Showing 6881-6890 of 7495 results for "".
- Dermira Completes Patient Enrollment for Third Cimzia Phase 3 Trial in Psoriasis Programhttps://practicaldermatology.com/news/dermira-completes-patient-enrollment-for-third-cimzia-phase-3-trial-in-psoriasis-program/2458760/Dermira, Inc., completed its patient enrollment for the CIMPACT clinical trial of CIMZIA® (certolizumab pegol) in adult patients with moderate-to-severe chronic plaque psoriasis. The CIMPACT study is the third and final clinical trial of the CIMZIA Phase 3 development program in moderate-to-s
- Ranbaxy Launches Patient Education Resources for Acne Patients Featuring Athlete Kelly Clarkhttps://practicaldermatology.com/news/ranbaxy-launches-patient-education-resources-for-acne-patients-featuring-athlete-kelly-clark/2458758/Ranbaxy Laboratories Inc, a SUN PHARMA company, has launched of a variety of patient education resources featuring gold medal-winning snowboarder and 2015 ESPY Best Female Action Sports Athlete Kelly Clark. The tools are housed on ABSORICA.COM. Absorica<
- Allergan Expands Neurotoxin Pipeline with Anterios Acquisitionhttps://practicaldermatology.com/news/allergan-expands-neurotoxin-pipelinewith-anterios-acquisition/2458763/Allergan plc has acquired Anterios, Inc., a clinical stage biopharmaceutical company developing a next generation delivery system and botulinum toxin-based prescription products. Under the terms of the agreement, Allergan acquired Anterios for an upfront payment of $90 million and potential devel
- Anacor Submits NDA for Crisaborole Topical Ointment, 2% for the Treatment of Mild-to-Moderate Atopic Dermatitishttps://practicaldermatology.com/news/anacor-submits-nda-for-crisaborole-topical-ointment-2-for-the-treatment-of-mild-to-moderate-atopic-dermatitis/2458765/Anacor Pharmaceuticals, Inc. has submitted a New Drug Application (NDA) to the US FDA seeking approval of crisaborole topical ointment, 2%, a novel non-steroidal topical anti-inflammatory phosphodiesterase-4 (PDE-4) inhibitor in development for the potential treatment of mild-to-moderate atopic d
- Paratek To Complete Omadacycline Phase 3 Skin Trial Earlier Than Expectedhttps://practicaldermatology.com/news/paratek-completes-enrollment-for-omadacycline-phase-3-skin-trial-earlier-than-expected/2458767/Paratek Pharmaceuticals, Inc. may report top-line data from its ongoing pivotal Phase 3 clinical trial evaluating omadacycline for the treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSS
- Valeant Announces J. Michael Pearson Will Be On Medical Leave of Absencehttps://practicaldermatology.com/news/valeant-announces-j-michael-pearson-will-be-on-medical-leave-of-absence/2458770/Valeant Pharmaceuticals International, Inc. announced that chairman and chief executive officer J. Michael Pearson will be on a medical leave of absence, effective immediately. The company's board of directors has created an Office of the Chief Executive Officer, which will include Robert Cha
- Brickell Biotech Achieves Positive Phase 2b Results for BBI-4000 for Hyperhidrosishttps://practicaldermatology.com/news/brickell-biotech-achieves-postive-phase-2b-results-for-bbi-4000-for-hyperhidrosis/2458772/Brickell Biotech, Inc. shared the results of its Phase 2b study of BBI-4000 (sofpironium bromide) for the topical treatment of primary axillary hyperhidrosis, or excessive underarm sweating. The multicenter, randomized, double blind, vehicle-controlled Phase 2b study was designed to evaluate the
- MELA Sciences Changing Name to STRATA Skin Sciences to Reflect Broader Dermatology Commitmenthttps://practicaldermatology.com/news/mela-sciences-changing-name-to-strata-skin-sciences-to-reflect-broader-dermatology-commitment/2458771/MELA Sciences, Inc. will be changing its corporate name to STRATA Skin Sciences, Inc. effective Tuesday, January 5, 2016 and it will trade under the symbol “SSKN” on the Nasdaq Stock Market. Michael R. Stewart, President and Chief Executive Officer stated: “Our June 2015
- Strathspey Crown Appointments Murthy Simhambhatla, PhD, as Senior Partnerhttps://practicaldermatology.com/news/strathspey-crown-appointments-murthy-simhambhatla-phd-as-senior-partner/2458776/Strathspey Crown Holdings LLC announced the appointment of Murthy Simhambhatla, PhD as a Senior Partner of the firm. Dr. Simhambhatla has more than 20 years of experience in bioscience and has built a successful track record in the healthcare industry. Dr. Simhambhatla was
- ASDS Goes Triple Platinum in MarCom Awardshttps://practicaldermatology.com/news/asds-goes-triple-platinum-in-marcom-awards/2458778/The American Society for Dermatologic Surgery and American Society for Dermatologic Surgery Association were recognized with 14 awards – including three Platinums – in the 2015 MarCom Awards competition. The MarCom Awards is an international competition administered and judged by the